Fundraising FoxDeerfield Management Company
Venture capitalNew York · Seed–Late Stage · 144 people tracked
Also known as DEERFIELD MANAGEMENT COMPANY, L.P.
Find your way into Deerfield Management Company
Sign up to see every warm intro you have to Deerfield Management Company
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Deerfield Management Company team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Deerfield Management is dedicated to advancing healthcare by investing across the healthcare ecosystem, with a primary focus on therapeutics, medical devices, and healthcare services. It supports a portfolio of more than two hundred private and public companies, aiming to cure disease, improve quality of life, and reduce the cost of care. The firm combines capital with a dedicated intelligence team that gathers and analyzes healthcare data and market research to guide investment decisions. Deerfield also runs an employee-funded foundation focused on children's health worldwide, and its Innovation at Cure infrastructure in New York City helps mature and advance development-stage and commercial assets in partnership with strategic and corporate partners.
Source: firm website, verified Oct 17, 2026.
Team · 144 people
from the firm's website & public directories
President of the Deerfield Foundation.
Managing Partner on the investment team with portfolio oversight responsibilities.
Partner on the investment medical technologies team.
Managing Director for data science and engineering within Deerfield Intelligence.
A partner on Deerfield's Medical Technologies team who joined in 2017, previously a principal at Longitude Capital investing in medtech and biotech and an associate in JPMorgan's healthcare investment banking practice. He is a trained surgeon with an M.D. from the Mayo Clinic, an M.P.H. and M.B.A. from Harvard, and residency training at Harvard's Brigham and Women's Hospital and Stanford.
Partner on the investment medical technologies team with portfolio and private investment process oversight.
Partner at Deerfield who joined in 2012, overseeing public fund processes and conducting research on healthcare companies. Previously a portfolio manager at S Squared Technology, an analyst at Amaranth Advisors, and an equity analyst at Lehman Brothers and Lazard Frères. Holds a B.A. from Johns Hopkins and an M.D. from SUNY Syracuse.
Managing Director on the investment therapeutics team.
David Greenwald is a Managing Director at Deerfield Management, a healthcare investment firm focused on public and private companies, where he identifies investment opportunities and holds operational and board roles at private portfolio companies. He previously served as Director of Business Development and Corporate Partnerships at Johns Hopkins Technology Ventures and as Director of Client Solutions at Decision Resources Group, which acquired Relay Technology Management, a company he co-founded in 2008. He has lectured on entrepreneurial and corporate finance at the Johns Hopkins Carey Business School and at Tufts University, and holds a Ph.D. in Genetics from the Tufts University Sackler School of Graduate Biomedical Sciences.
Managing Director on the investment public structured finance team.
Partner on the investment therapeutics team.
Managing Director for data analytics within Deerfield Intelligence, focused on data analytics and market insights.
Partner on the investment therapeutics team.
Partner and chief financial officer for funds within business operations finance.
Operating partner on the investment healthcare services team.
Partner and chief partnerships officer within business operations partnerships.
Partner on Deerfield's Therapeutics team since 2021, focused on research and analysis of healthcare companies. Previously a biotech research analyst, including as Managing Director at Stifel, Director at Deutsche Bank, and VP at JMP Securities, and earlier a biomedical researcher. Holds a B.A. from Stony Brook and an M.D. from Weill Cornell.
Partner on the investment therapeutics team.
Partner within business operations legal and compliance.
Managing Director on the investment medical technologies team.
Partner on the investment therapeutics team.
Partner and head equity-linked and credit trader on the investment public structured finance and trading teams.
Partner on the investment therapeutics team.
Brian Chow is a Managing Director on the Therapeutics team at Deerfield Management, which he joined in 2022. He previously spent a decade at the University of Pennsylvania, most recently as an Associate Professor of Bioengineering, and earlier held roles as Head of Research Operations and Alliances at Sage Therapeutics and as a Venture Associate at Third Rock Ventures. He earned a B.S. in Chemistry from Stanford University and a Ph.D. in Media Arts and Sciences from MIT.
Partner on the investment healthcare services team.
Managing Director on the investment medical technologies team.
Nicholas Bishop is a Partner on Deerfield's Therapeutics team, which he joined in 2014, focusing on research and analysis of companies in the healthcare industry. He previously spent four years as a biotechnology research analyst at Cowen and Company and worked as a biomedical research scientist at Harvard University and MIT. He holds a B.A. with honors from Rice University and a Ph.D. from MIT, and has published scientific articles on the genetic regulation of aging and lifespan.
Partner on the investment public structured finance team.
Partner on the investment healthcare services team.
Principal for investment strategy with portfolio oversight responsibilities.
Principal on the investment healthcare services team.
Principal on the investment medical technologies team.
Principal on the investment healthcare services team.
Senior director of biologics within Deerfield Discovery and Development.
Desktop support engineer within business operations IT.
Director of product and strategy within Deerfield Intelligence.
Analyst on Deerfield's investment therapeutics team.
Associate on the investment therapeutics team.
Director of data engineering within Deerfield Intelligence.
Manager supporting the therapeutics team within business operations administration.
Director of learning and development within business operations HR.
Anthony Barsotti is a Senior Director of Preclinical Pharmacology at Deerfield Discovery and Development, joining the firm in 2020. He previously held research roles at Inzen Therapeutics, Kadmon Corporation, and Pfizer, and holds a B.A. from the University of Pennsylvania and a Ph.D. from Columbia University.
Senior director of preclinical pharmacology within Deerfield Discovery and Development.
Assistant general counsel within business operations legal and compliance.
Director of product and strategy within Deerfield Intelligence.
Director of software engineering within Deerfield Intelligence.
Executive assistant within business operations administration.
Executive assistant within business operations administration.
Vice president of preclinical pharmacology within Deerfield Discovery and Development.
Counsel for portfolio company operations within business operations legal and compliance.
Systems engineer within business operations IT.
Coco Dong, Ph.D. is a Director of Quantitative Applications on the Deerfield Intelligence team, having joined Deerfield in 2020 as a Senior Genetic Data Scientist before moving to the Intelligence team in 2023. She previously worked as a strategist at Goldman Sachs and a principal statistician at GlaxoSmithKline, and holds an M.S. in Computer Science and a Ph.D. in Biostatistics from USC.
Director of quantitative applications within Deerfield Intelligence quantitative research.
Managing Director of global market research within Deerfield Intelligence.
Head of financial operations within business operations finance.
Associate director of market research within Deerfield Intelligence.
Director of cloud platform engineering within business operations IT.
Senior associate for investor business development within business operations partnerships.
Director of project management within Deerfield Discovery and Development.
Associate director of market research within Deerfield Intelligence.
Senior director of applied epidemiology within Deerfield Intelligence.
Senior compliance officer and counsel within business operations legal and compliance.
Communications associate within business operations.
Director of quantitative research within Deerfield Intelligence.
Senior transactions counsel within business operations legal and compliance.
Compliance associate within business operations legal and compliance.
Senior director of preclinical pharmacology within Deerfield Discovery and Development.
Director of compliance within business operations legal and compliance.
Infrastructure engineer within business operations IT.
Contact for communications inquiries at Deerfield.
Director of quantitative research within Deerfield Intelligence.
Executive assistant within business operations administration.
Senior controller for fund finance within business operations.
Chief property and development officer overseeing building operations.
Senior advisor on the investment healthcare services team.
Senior director of preclinical pharmacology within Deerfield Discovery and Development.
Director of AI engineering within Deerfield Intelligence.
Manager of recruiting and employee experience within business operations HR.
Director of talent acquisition for portfolio company operations within external operations.
Director of product and strategy within Deerfield Intelligence.
Senior scientist in protein sciences within Deerfield Discovery and Development.
Associate director of cybersecurity within business operations IT.
Head of portfolio company operations within external operations.
Executive assistant within business operations administration.
Trader on the investment trading team.
Director of software engineering within Deerfield Intelligence.
Head of strategy and operations within Deerfield Intelligence.
Senior associate for investor relationship management within business operations partnerships.
Principal scientist in preclinical pharmacology within Deerfield Discovery and Development.
Senior director of business intelligence within Deerfield Intelligence.
Senior director of portfolio strategy and innovation within Deerfield Discovery and Development.
Senior controller for corporate finance within business operations.
Associate director on the investment therapeutics team.
Application developer within Deerfield Intelligence engineering.
Associate director and solutions and support manager within business operations IT.
Director of AI engineering within Deerfield Intelligence.
Desktop support engineer within business operations IT.
Director of innovation alliances within Deerfield Discovery and Development.
Executive assistant within business operations administration.
Senior director of market access within Deerfield Intelligence.
Coordinator within business operations partnerships.
Director of DMPK and quantitative system pharmacology within Deerfield Discovery and Development.
Senior director of data integrity and operations within external operations.
Vice President of Translational Immunology within Deerfield Discovery and Development, having joined Deerfield in 2024. She previously held translational biology and immuno-oncology research leadership roles at TRex Bio, Five Prime Therapeutics, and Amplimmune, and holds an A.B. from Harvard and a Ph.D. in Biology from Caltech.
Vice president of translational immunology within Deerfield Discovery and Development.
Senior project manager for IT within business operations.
Vice president of portfolio company operations HR and strategy within external operations.
What they invest in
from 94 of 125 portfolio companiesHealthtech ×55Biotech ×51Medical Devices ×28Digital Health ×22AI & Machine Learning ×21Deep Tech ×9SaaS ×8Enterprise Software ×5
HQs:United States×84Chile×1United Kingdom×1Israel×1Philippines×1
Investments · 125 tracked
founders shown can be your intro pathBy year:2026 · 42025 · 72024 · 92023 · 42022 · 152021 · 92020 · 132019 · 42018 · 92017 · 42016 · 42015 · 696 dated
BiomX builds a portfolio of defense and security companies through subsidiaries, partnerships, and acquisitions, focusing on detection systems, aerial technologies, and infrastructure security.
AI & Machine LearningBiotechCybersecurityDeep TechDefense TechHardwareNess Ziona
Jonathan Solomon(Chief Executive Officer)inMerav Bassan(Chief Development Officer)inMarina Wolfson(Chief Financial Officer)inJesse Goodman(Director)Alan Moses(Director)Jonathan Leff(Director)
Co-investorsAMR Action FundBaruch Future VenturesNSG VenturesOrbiMedSBI JI Innovation Advisory Ltd.Seventure Partners+2 more
Black Diamond Therapeutics develops small-molecule kinase inhibitors targeting families of oncogenic mutations across cancer types, including its lead candidate silevertinib for EGFR-mutant lung cancer and glioblastoma.
Elizabeth Buck(Chief Scientific Officer)inBrent Hatzis-Schoch(Chief Operating Officer and General Counsel)inSergey Yurasov(Chief Medical Officer)inMelanie Morrison(Chief Development Officer)
Co-investorsLAVLilly Asia VenturesNew Enterprise Associates (NEA)Nextech InvestNSG VenturesRA Capital+4 more
Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies for patients with autoimmune diseases.
BiotechHealthtechRadnor, US
Steven Nichtberger(Founder)inDan Geffken(Executive Officer)inAnup Marda(Chief Financial Officer)inMark Simon(Director)
BoardBrian Daniels(Director)in
Co-investors5AM VenturesBain Capital Life Sciences
Edgewise Therapeutics discovers and develops small molecule medicines targeting muscle proteins to treat neuromuscular and cardiac diseases, including sevasemten for muscular dystrophies and EDG-7500 for cardiomyopathy, leveraging a proprietary drug discovery platform based on muscle physiology and high-throughput functional assays.
BiotechDigital HealthBoulder, US
Kevin Koch(Executive Officer, Director)inAlan Russell(Director)inBadreddin Edris(Director and Co-Founder)inKenneth Harrison(Director)
BoardPeter Thompson(Director)inJonathan Root(Director)in
Co-investorsBoulder VenturesForesite CapitalOrbiMedUS Venture PartnersViking GlobalWellington Management+1 more
Editas Medicine develops gene editing medicines using CRISPR/Cas9 and CRISPR/Cas12a technology to treat serious diseases including blood disorders, cardiovascular conditions, and cancer.
BiotechDeep TechMedical DevicesCambridge, US
Feng Zhang(Founder)inGeorge Church(Scientific Founder, Professor of Genetics, Harvard University and MIT)inKeith Joung(Scientific Founder, Professor of Pathology, Harvard Medical School)inDavid Liu(Scientific Founder, Professor of Chemistry and Chemical Biology, Harvard University)inKatrine Bosley(Executive Officer, Director)inVic Myer(Executive Officer)in
Co-investorsEcoR1 CapitalGV (Google Ventures)Sofinnova VenturesViking GlobalAtlas VentureFlagship Ventures+2 more
Foghorn Therapeutics is a clinical-stage biotech developing chromatin-targeted cancer drugs via its Gene Traffic Control platform, including a candidate co-developed with Eli Lilly.
Adrian Gottschalk(President and Chief Executive Officer)
Co-investorsFlagship PioneeringXeraya CapitalBiotechnology Value Fund
GeneDx provides advanced genetic testing and clinical interpretation services to help clinicians diagnose rare and inherited genetic disorders, with AI-driven genomic intelligence that supports patient care decisions and accelerates research and drug discovery.
AI & Machine LearningBiotechDigital HealthHealthtech
Katherine Stueland(CEO)in
Co-investorsOak HC/FT
Kiniksa is a global biopharmaceutical company that discovers and develops novel therapies for patients with unmet medical needs, with a focus on cardiovascular diseases and related conditions.
BiotechMedical DevicesHamilton
THOMAS W BEETHAM(Executive Officer)inSanj K. Patel(Chief Executive Officer and Chairman of the Board)
BoardSTEPHEN R BIGGAR(Director)FELIX J BAKER(Director)G. BRADLY COLE(Director)RICHARD S LEVY(Director)
Co-investorsSofinnova VenturesSofinnova Venture Partners
Mirum Pharmaceuticals is a biopharmaceutical company that develops and delivers therapies for people living with rare diseases.
BiotechHealthtechSan Diego, US
Chris Peetz(Co-founder & Chief Executive Officer)inEric Bjerkholt(Executive Officer)inPeter Radovich(Executive Officer)in
BoardPatrick Heron(Director)inMichael Grey(Director)Timothy Walbert(Director)
Co-investorsChiesi VenturesFrazier Life SciencesLongitude CapitalMESA VERDE VENTURE PARTNERSNew Enterprise Associates (NEA)Pappas Capital+4 more
Pacific Biosciences develops long-read DNA and RNA sequencing platforms and kits for genomics research, including whole genome, targeted, epigenetic, and RNA sequencing applications.
BiotechDeep TechMedical DevicesMenlo Park, US
Christian O. Henry(Executive Officer, Director)inJeff Eidel(Executive Officer)inSusan G. Kim(Executive Officer)inMark Van Oene(President and Chief Executive Officer)
BoardWilliam W. Ericson(Director)Hannah A. Valantine(Director)
Co-investorsDag VenturesKleiner PerkinsMaverick CapitalMohr Davidow VenturesThe Blackstone Group
Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.
AI & Machine LearningBiotechDeep TechMedical Devices
Mathai Mammen(CEO, President and Chairman)in
Co-investorsARCH Venture PartnersCatalio Capital Management, LPForesite CapitalFrazier Life SciencesGeneral CatalystGV (Google Ventures)+9 more
.png)
SCYNEXIS is a biopharmaceutical company focused on developing drug therapies for severe rare diseases, including anti-infective and antifungal treatments.
BiotechMedical DevicesDurham, US
Yves J. Ribeill(Executive Officer, Director)inCharles F. Osborne, Jr.(Executive Officer)Brian Schwab(Executive Officer)inDavid Angulo(President & Chief Executive Officer)inEric Sukenick(General Counsel)Sanjay Subramanian(Chief Financial Officer)
Co-investorsDecheng CapitalForesite CapitalRA Capital
Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.
BiotechHealthtechWaltham, US
René Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Christopher Frankenfield(Chief Financial and Operating Officer)inKatarina Luptakova(Chief Medical Officer)inPaul Clancy(Director)
Co-investorsBain Capital Life SciencesBay City CapitalF-Prime CapitalM VenturesMRL Ventures FundRA Capital+9 more
MMI develops miniaturized robotic surgical instruments and platforms to enable surgeons to perform complex microsurgery and supermicrosurgery on delicate anatomical structures with greater precision.
HealthtechMedical DevicesRoboticsJacksonville, US
Mark Toland(Executive Officer, Director)inAndrew Cleeland(Director)Justin Lynch(Director)inTheresa Jean Cameron(Director)Caleb Moore(Executive Officer)Augusto Vianna Castello(Director)
Board seatAndrew ElBardissi· per SEC Form D
Co-investorsAndera PartnersBioStar CapitalFidelity InvestmentsRA CapitalCorewell Health VenturesFountain Healthcare Partners
NXT Biomedical is a medical device incubator that develops and spins out startups building clinical medical technologies aimed at addressing unmet needs and reducing healthcare costs.
BiotechHealthtechMedical DevicesIrvine, US
Stanton Rowe(CEO)inDon Bobo(Director)
BoardKadhiresan V Kadir(Director)Steven Hochberg(Director)Andrew Cleeland(Director)
Board seatAndrew ElBardissi· per SEC Form D
Alo Solutions provides capital investment and practice transition support services for independent physicians seeking to expand their practices, plan for succession, or transition their patient panels.
Digital HealthEnterprise SoftwareFintechHealthtechSaaSRaleigh, US
Matt Eirich(CEO)inAngie Cain(Chief Administrative Officer)inLynn Gordon(Chief Legal & Compliance Officer)in
Pleno develops a genomic testing instrument platform designed to make multiomics testing faster, lower-cost, and higher-plex than existing methods like NGS, PCR, and microarrays.
BiotechHardwareHealthtech
Co-investorsForesite CapitalMedical Excellence Capital
SpectraWAVE develops optical and computational imaging technologies to diagnose and guide treatment decisions for patients with coronary artery disease and cardiovascular disease.
AI & Machine LearningDeep TechHealthtechMedical DevicesBedford, US
Eman Namati(President & CEO)inGuillermo Tearney(Founder; Professor of Pathology, Massachusetts General Hospital)Gregg Stone(Founder; Professor of Medicine, Mount Sinai Heart Health System)James Muller(Founder; Cardiologist, Brigham and Women's Hospital)inJeffrey O'Donnell(Founder; Managing General Partner, Runway Healthcare)Vivek Walimbe(Chief Operating Officer)in
Co-investorsLumira VenturesS3 VenturesSV Health InvestorsJohnson & Johnson Innovation – JJDC
HealthtechCarlsbad, US
Christoph Scharf(Director)inRandy Werneth(Executive Officer, Director)Graydon Beatty(Executive Officer)inVince Burgess(Director)inJohn Dahldorf(Executive Officer)
BoardAditya Puri(Director)
Board seatAndrew ElBardissi· per SEC Form D
Co-investorsAdvent Life SciencesOrbiMedXeraya CapitalFormation GroupGE VenturesIndex Ventures
Adela develops blood-based tests for cancer detection using epigenetics and liquid biopsy technology, aimed at helping patients and clinicians detect and act on cancer earlier.
BiotechDigital HealthHealthtechMedical DevicesFoster City, US
Daniel Diniz De Carvalho(Executive Officer, Promoter)Scott Bratman(Executive Officer, Director)inAnne-Renee Hartman(Founder)inAlan Williams(Executive Officer)inLisa Alderson(Executive Officer, Director)inPriscilla Huang(Executive Officer)in
Board seatAndrew ElBardissi· per SEC Form D
Co-investorsDecheng CapitalF-Prime CapitalOrbiMedMenlo Ventures
Appello Pharma is a biopharmaceutical company focused on drug discovery and development for neurological and metabolic diseases.
BiotechDigital HealthHealthtechMedical DevicesNashville, US
Dr. Laden(Co-founder)Christopher Rand(Executive Officer)Vaughn Bryson(Director)Jeff P. Conn(Director)
BoardWilliam Slattery(Director)Howie Furst(Director)in
Board seatHoward Furst· per SEC Form D · $13.5M raise · filed Jan 2022
Co-investorsMountain Group CapitalRelevance Ventures
Ascertain provides an agentic AI platform that automates healthcare administrative work such as prior authorizations, referrals, eligibility checks, and care coordination by integrating with existing systems and embedding human review.
AI & Machine LearningDigital HealthHealthtechNew York, US
Mark Michalski(Executive Officer, Director)inMarc Berger(Executive Officer)Gregg Fergus(Executive Officer, Director)Laurence Kraemer(Executive Officer)Carlos Dedesma(Executive Officer)Courtney Marcin(Director)
Board seatMoses AdubiJulian Harris· per SEC Form D
Co-investorsAegis Ventures
BiotechSan Francisco, US
Matthew Patterson(Executive Officer, Director)in
BoardJonathan Silverstein(Director)inSteve Squinto(Director)inKush Parmar(Director)inThomas Woiwode(Director)
Board seatJonathan Leff· per SEC Form D
Co-investorsAsset Management CompanyRA CapitalvenBio Partners5AM VenturesOrbiMedVenrock
Aurion Biotech develops regenerative cell therapies for ophthalmology, focused on treating blindness and vision loss from corneal endothelial disease.
BiotechHealthtechMedical DevicesSeattle, US
DAVID ROSTOV(Executive Officer)inGREG KUNST(Executive Officer, Director)PATRICK LALLY(Director)JEANNETTE BANKES(Director)CHRISTINE MCCAULEY(Director)ARNAUD LACOSTE(Executive Officer)
Board seatAndrew ElBardissi· per SEC Form D
Co-investorsVisionary VenturesFlying L Partners
Axon Therapies develops the SAVM procedure, an implant-free catheter-based ablation therapy that targets the right greater splanchnic nerve to reduce overactive sympathetic nerve activity in patients with heart failure with preserved ejection fraction (HFpEF).
HealthtechMedical DevicesNew York, US
Howard R. Levin(Executive Officer, Director)Mark Gelfand(Executive Officer)Zoar Engelman, PhD(President & CEO)Chad Hoskins(President & Chief Executive Officer)
BoardPaul LaViolette(Director)in
Board seatAndrew ElBardissi· per SEC Form D · $15M raise · filed Feb 2019
Co-investorsStar51 CapitalAction Potential Venture Capital Ltd.Earlybird Venture CapitalSV Health Investors
Dracen Pharmaceuticals is a private drug developer working at the intersection of cancer metabolism and immuno-oncology, developing glutamine antagonists that inhibit tumor glutamine metabolism and remodel the tumor microenvironment.
BiotechHealthtechBaltimore, US
Robert Wild(Co-founder & Chief Scientific Officer)Thomas M. Estok(Chief Executive Officer, President and Treasurer)Drew Pardoll, M.D., Ph.D.(Director)
BoardRobert Jackson(Director)
Board seatJonathan Leff· per SEC Form D
Co-investorsBiotech Investments S.R.Oi&i Biotech FundOUP (Osage University Partners)Sofinnova Ventures
Element Science is a medical technology company that develops the Jewel, an FDA-approved adhesive-based wearable cardioverter defibrillator designed to protect patients at risk of sudden cardiac arrest.
AI & Machine LearningDigital HealthHardwareHealthtechMedical DevicesSan Francisco, US
Uday N. Kumar(Executive Officer, Director)inUday Kumar(Founder)in
BoardRussell Hirsch(Director)Neil Exter(Director)inKrishna Yeshwant(Director)inWilliam H. Kucheman(Director)
Board seatAndrew ElBardissi· per SEC Form D · $145.6M raise · filed Mar 2020
Co-investorsGV (Google Ventures)Third Rock VenturesQiming Venture Partners
Clinical-stage biotech developing next-generation polyene antifungals for life-threatening invasive fungal infections.
BiotechNew York, US
Kieren Marr(Executive Officer, Director)
BoardJim Flynn(Director)Martin Heidecker(Director)in
Board seatJonathan Leff· per SEC Form D
Co-investorsAMR Action FundIllinois Ventures
Incardatherapeutics develops drug therapies for treating atrial fibrillation using synergistic combinations of anti-arrhythmic agents, with delivery platforms designed for both hospital and at-home settings.
BiotechDigital HealthMedical DevicesBrisbane, US
Carlos A. Schuler(Executive Officer, Director)inJohn S. Patton(Executive Officer, Director)inRangachari Narasimhan(Executive Officer, Director)Grace Colon(Executive Officer, Director)inMiller Samantha(Executive Officer)
BoardMcCarthy Reenie(Director)
Board seatAndrew ElBardissi· per SEC Form D
Co-investorsAsset Management CompanyHealthCapSofinnova Ventures
BiotechNew York, US
Nader Halim(Executive Officer, Director)Althea Stillman(Executive Officer, Director)
BoardDavid Greenwald(Director)in
Board seatJonathan Leff· per SEC Form D
Co-investorsBioAdvance
NeoChord develops a medical device system for beating heart mitral valve repair in patients with mitral valve regurgitation.
Advanced ManufacturingHealthtechMedical DevicesMaple Grove, US
Todd Berg(Executive Officer, Director)inDavid H. Chung(Executive Officer, Director)inRon Nelson(Executive Officer)in
BoardCasey Tansey(Director)Mudit K. Jain(Director)
Board seatAndrew ElBardissi· per SEC Form D
Co-investorsBaird CapitalTreo Ventures, LlcUS Venture PartnersU.S. Venture Partners
Reprieve Cardiovascular develops a decongestion management system that uses real-time patient data to guide and personalize diuretic therapy for fluid removal in heart failure patients.
Digital HealthHealthtechMedical DevicesMilford, US
Tony Fields(Executive Officer)Adam Bartnik(Executive Officer)inMark Pacyna(Executive Officer, Director)inJim Dillon(Executive Officer, Director)Hanson S. Gifford III(Director)Gregory W Mann(Executive Officer)
Board seatAndrew ElBardissi· per SEC Form D
Co-investorsArboretum VenturesLightstone VenturesRex Health VenturesGenesis Venture CapitalSante Ventures
Neomorph develops a molecular glue discovery platform to identify small-molecule medicines that degrade disease-causing proteins through targeted protein degradation.
AI & Machine LearningBiotechDeep TechSan Diego, US
Co-investorsLongwood Fund
Actio is a precision medicine company that translates genetic insights into new therapeutics, developing drugs that target the genes underlying both rare diseases and more prevalent conditions.
AI & Machine LearningBiotechDeep Tech
David Breckenridge(Founder)inDavid B. Goldstein(Founder)
Co-investorsCanaan PartnersDroia VenturesEcoR1 Capital
Aphage develops AI and sensor technologies to identify, track, and classify physical threats across borders, infrastructure, and transportation networks for government and security organizations.
AI & Machine LearningBiotechDefense TechGovTechGaithersburg, IL
Gregory L. Merril(Executive Officer, Director, Promoter)Carl R. Merril(Executive Officer, Director)in
BoardJonathan Leff(Director)inEvan Loh(Director)Jana Jensen(Director)Raymond L. Martz(Director)
Co-investorsHackensack Meridian Health Bear's DenMaryland TEDCOTEDCOAMR Action FundSofinnova Ventures
AlpfaMed develops a Pulsed Field Ablation (PFA) technology that uses targeted, heat-free electrical energy to remodel prostate tissue and treat Benign Prostatic Hyperplasia (BPH).
HealthtechMedical DevicesPalo Alto, US
Allan Zingeler(Executive Officer, Director)inMichael Wiley(Executive Officer, Director)inRupa Patel(Executive Officer)
BoardDavid Bonita(Director)Andrew ElBardissi(Director)Michael Hurley(Director)
Annexon is a clinical-stage biopharmaceutical company developing C1q and classical complement pathway inhibitors to treat complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders.
BiotechHealthtechMedical DevicesSo. San Francisco, US
Ben Barres(Scientific Co-Founder)Douglas Love(Founder)inMark L Smith(Executive Officer)Campbell Murray(Director)inThomas Wiggans(Director)Ricky Sun(Director)
Co-investorsBain Capital Life SciencesCorrelation VenturesNew Enterprise Associates (NEA)BlackRockBlackstone Life SciencesClarus Ventures+2 more
Boulevard Bio is a clinical-stage precision immunology company developing multi-specific antibody therapies for B cell-driven autoimmune diseases, with a lead program targeting IgA nephropathy.
BiotechHealthtech
Cohere Health provides a platform aimed at aligning the interests of patients, physicians, and health plans to support care decisions and improve member outcomes.
AI & Machine LearningDigital HealthEnterprise SoftwareHealthtechSaaSBoston, US
Siva Namasivayam(Executive Officer, Director)inRobert Shepardson(Executive Officer)inKristen Carucci(Executive Officer)inDuncan Reese(Executive Officer)
BoardDavid Barrett(Director)Amir Debourou(Director)
Co-investorsCota CapitalFlare Capital PartnersLongitude CapitalDefine VenturesPolaris PartnersTemasek
ConcertoCare provides coordinated in-home and center-based medical, behavioral, and social care for seniors and adults with complex care needs who have Medicare, Medicare Advantage, or Medicare+Medicaid coverage.
Digital HealthHealthtechLongevity
Co-investorsAtento CapitalObvious VenturesSteelSky VenturesAddeparArboretum VenturesVast Ventures+1 more
Cortica provides in-home, in-clinic, and telehealth neurological therapies for children with autism and developmental differences, integrating neurological, biomedical, behavioral, speech-language, and sensorimotor treatments.
Digital HealthHealthtechMedical DevicesSan Diego, US
Dr. Suzanne Goh(Founder)Neil Hattangadi(Co-Founder and Chief Executive Officer)inBriana Elvaiah(Executive Officer)inSuzanne Goh-Hattangadi(Founder)Suzanne Goh, MD, BCBA(Co-Founder and Chief Medical Officer)
BoardRyan Drant(Director)in
Co-investors.406 VenturesAIFAPERTURE Venture PartnersCVS Health VenturesEcho Health VenturesLongitude Capital+6 more
cystetic Medicines is a drug development company creating an inhaled dry-powder therapy based on an FDA-approved antifungal compound to treat cystic fibrosis, targeting the roughly 10% of patients not helped by existing modulators.
BiotechHealthtechMedical DevicesChampaign, US
MARTIN BURKE, MD., PH.D.(Director)Dr. Martin D. Burke(Co-founder)Dr. Michael J. Welsh(Co-founder)Dr. Jeffry Weers(Chief Technology Officer)PETER W STEELMAN(Director)inJONATHAN RAMOS(Director)
Co-investorsIllinois Ventures
Deerfield Catalyst is a medtech incubator that develops medical technology solutions aimed at improving patient outcomes and care delivery.
HealthtechMedical Devices
Howard Levin(CEO & CMO)inMark Gelfand(Chief Technology Officer)inZoar Engelman(Chief Science Officer)inAdam Rosenwach(Chief Business Officer)inMaybelle Jordan(Chief Strategy Officer)in
Co-investorsStar51 Capital
ElevenLabs is an AI research and product company that builds voice generation and audio processing platforms for creating human-like voice interactions with technology.
AI & Machine LearningCreator EconomyEnterprise SoftwareSaaSLondon, GB
Mati Staniszewski(Founder)inPiotr Dabkowski(Co-founder)inHannah C(Founder)Mateusz Jakub Staniszewski(Co-founder)inMati Staniszewski Piotr Dabkowski(Founder)Piotr Dąbkowski(Founder)
Co-investorsA.Capital VenturesAir Street CapitalAlkeon InnovationAndreessen HorowitzAntiAspire11+47 more
Eligible provides APIs that healthcare businesses use to manage insurance billing and claims processing.
Developer ToolsHealthtechNew York City, US
Katelyn Gleason(CEO)James Schuler(CTO)inPatrice Krakow
Co-investorsJames Beshara FundY CombinatorAndreessen HorowitzAnvil CapitalAthena AdvisorsGeneral Catalyst+3 more
San Diego protein-sequencing company behind the ProteoCode platform; ceased operations in late 2025.
Co-investorsARCH Venture PartnersDecheng CapitalAlexandriaGV (Google Ventures)Nan Fung Life SciencesNorthpond Ventures
Excelsior Sciences develops automated chemistry technology for small-molecule discovery and manufacturing, targeting pharmaceutical and materials development.
AI & Machine LearningBiotechDeep Tech
Marty BurkeBartosz GrzybowskiMichael Foley(CEO)inJana Jensen(COO)in
Co-investorsKhosla VenturesSofinnova PartnersCornucopian Capital ManagementIllinois Ventures
Frontier is a drug discovery company developing small-molecule covalent drugs aimed at previously undruggable protein targets across the proteome.
AI & Machine LearningBiotechSouth San Francisco, US
Chris Varma, Ph.D.(Executive Officer, Director)Chris Varma(Co-founder, Chairman and CEO)inJim Winkler(Executive Officer)Johannes Hermann, Ph.D.(Executive Officer)Kevin Webster(Executive Officer)inGregory Chow(Executive Officer)
Co-investorsBerkeley CatalystDCVC (Data Collective)Droia VenturesFelicis VenturesMPM BioImpactRA Capital+2 more
BiotechCambridge, US
Geoff McDonoughy(Executive Officer, Director)Glenn Goddard(Executive Officer)Mark Angelino(Executive Officer)
BoardJason Rhodes(Director)inCatherine Stehman-Breen(Director)Anthony Quinn(Director)
Co-investorsAtlas VentureForesite CapitalWellington ManagementCasdin CapitalF-Prime CapitalFidelity Investments+1 more
Hallux Inc. develops Hallux Subungual Gel (HSG), a physician-administered terbinafine treatment applied directly to the nail bed to treat onychomycosis (fungal nail infection).
BiotechHealthtechMedical DevicesLaguna Hills, US
Hendrik Arend Kroon(Executive Officer)Mark Taylor(Executive Officer, Director)inJay Birnbaum(Executive Officer, Director)
BoardPeter Steelman(Director)inZheng Su(Director)Bryan Sendrowski(Director)
Clinical-stage genetic medicines company using human-derived AAV vectors and nuclease-free gene editing for rare diseases.
BiotechBedford, US
Siyamak Rasty(Executive Officer)Albert Seymour(Executive Officer)
BoardSteven Gillis(Director)Arthur Tzianabos(Executive Officer, Director)Kush Parmar(Director)inRichard Gregory(Director)
Co-investors5AM VenturesARCH Venture PartnersOUP (Osage University Partners)AlexandriaFidelity InvestmentsHBM Healthcare Investments+5 more
Humanity offers an enterprise employee wellness platform that uses biological age monitoring to help teams improve health and productivity.
Digital HealthHealthtechHR TechLongevityWellness & Fitness
Peter Ward(Founder)in
Co-investorsOne Way Venturess16Scientia VenturesTrueSight VenturesAndreessen HorowitzJump Crypto+3 more
Humanity provides AI-powered employee scheduling and shift-planning software for frontline and enterprise workforces, automating schedule building, demand forecasting, and labor-cost control.
Future of WorkHR TechSaaSBoston, US
Peter Ward(Executive Officer, Director)inMichael Geer(Director)
Co-investorsPoint NineSaaS CapitalTeam Builder VenturesJumpstart Nova
Interleukin operates a B2B platform for sourcing and procuring medical products and services, letting registered buyers discover accredited suppliers, request quotes, send purchase orders, and pay on terms in one system.
B2B MarketplacesHealthtechMedical Devices
Co-investorsBuko VenturesJanus Henderson Investors
IntusCare builds a technology ecosystem for PACE (Programs of All-Inclusive Care for the Elderly) organizations, offering population health, utilization management, and risk adjustment tools to support care delivery, financial performance, and regulatory compliance.
AI & Machine LearningDigital HealthHealthtechProvidence, US
John Robert Felton(Executive Officer, Director)Robbie Felton(Founder)inEvan Jackson(Founder)inAlex Rothberg(Founder)in
BoardWilliam Helman(Director)inGilbert Addo(Director)
Co-investorsBlue Star Innovation PartnersEqual Opportunity VenturesFelicis VenturesGreen Egg VenturesJumpstart NovaService Provider Capital+4 more
Jaguar Gene Therapy develops gene therapy treatments for severe genetic diseases, focusing on AAV-based platform therapies designed to deliver one-time, long-lasting treatments.
BiotechHealthtechMedical DevicesLake Forest, US
Joseph NolaninJoe Nolan, MBA(Chief Executive Officer)
Co-investorsAIFARCH Venture PartnersJDRF T1D FundGoldman SachsSamsung Ventures
Lark provides AI-powered testing infrastructure for engineering teams that can test UIs, APIs, SDKs, and async workflows through natural language tests.
AI & Machine LearningDeveloper ToolsEnterprise SoftwareSan Francisco, US
Vijit Dhingra(Founder)inJack Brown(Founder)in
Co-investorsY CombinatorSteelSky VenturesAlpha Intelligence CapitalApplied AngelsArbor VenturesBridge Bank+4 more
Lark develops AI agents that automate manual workflows for wholesale distributors, integrating with their existing ERP systems and learning from each distributor's historical data and team decisions.
Advanced ManufacturingAI & Machine LearningSan Francisco, US
Jason Wang(CEO)inMichael Wang(Co-Founder)in
Co-investorsY CombinatorFranklin TempletonKing River Capital
Lumeris uses AI combined with human-centered design to address the U.S. primary care shortage, co-creating an AI tool called Tom with physicians and patients to deliver Primary Care as a Service.
AI & Machine LearningDigital HealthHealthtechSt. Louis, US
W. Michael Long(Chairman & Chief Executive Officer, Lumeris Group Holdings Corporation)
Co-investorsBlue Venture FundsHavencrest Capital ManagementKleiner PerkinsBlueCross BlueShield Venture PartnersSandbox Industries
Lumos Pharma is a clinical-stage biopharmaceutical company developing therapies for rare diseases, with a lead candidate targeting Pediatric Growth Hormone Deficiency.
BiotechHealthtechAustin, US
Richard John Hawkins(Executive Officer, Director)John C. McKew(President and Chief Scientific Officer)inPisit "Duke" Pitukcheewanont(Chief Medical Officer)inLori Lawley(Chief Financial Officer)inBrad Powers(Chief Compliance Officer and General Counsel)inCampbell Murray(Executive Chairman)in
Co-investorsNew Enterprise Associates (NEA)Roche Venture FundClarus VenturesSante Health VenturesSante VenturesWellcome Trust
San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.
BiotechSan Diego, US
Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)
BoardKristina Burow(Director)inRichard Heyman(Director)inAmir Nashat(Director)in
Co-investorsage1EcoR1 CapitalLAVLifeSci Venture PartnersLilly Asia VenturesNew Enterprise Associates (NEA)+8 more
myLaurel provides in-home medical care aimed at improving access for high-risk patients, working with clinicians and care teams.
Digital HealthHealthtech
Co-investorsBeresford VenturesCity LightFrist Cressey VenturesGV (Google Ventures)RevolutionSteelSky Ventures+1 more
HealthtechBranford, US
Sofia Noori(Executive Officer, Director)Mariam Malik(Executive Officer)in
BoardLaura Veroneau(Director)Adrienne Rosenthal(Director)
Co-investors.406 VenturesOptum Ventures
Nuvalent is a biopharmaceutical company focused on structure-based drug discovery and the development of precision oncology therapies.
BiotechHealthtechMedical DevicesCambridge, US
Matthew Shair(Director)inHenry Pelish, PhD(Chief Scientific Officer)R. Porter James(Executive Officer, Director)inJames Porter, PhD(Chief Executive Officer)Alex Balcom(Chief Financial Officer)inChristopher Turner, MD(Chief Medical Officer)
Co-investorsAvoro Capital AdvisorsBain Capital Life SciencesViking GlobalWellington Management
Octave is a mental health practice platform that connects licensed therapists with patients seeking in-network mental health care.
Digital HealthHealthtechMental HealthSaaSSan Francisco, US
Sandeep Acharya(Founder, CEO)inDavid White(Executive Officer)in
BoardSaurabh Bhansali(Director)inEllie Wheeler(Director)Craig Cimini(Director)
Co-investorsFelicis VenturesGreycroftHealthier CapitalNat TurnerObvious VenturesCompany Ventures+3 more
Cambridge, US
Christophe Queva(Executive Officer)inTheodore Ashburn(Executive Officer, Director)Alon Lazarus(Director)Cameron Wheeler(Director)in
BoardBriggs Morrison(Director)inMitchell Finer(Executive Officer, Director)
Co-investorsAstellas Venture Management LLCCowen Healthcare InvestmentsIMM InvestmentK2 HealthVenturesMPM BioImpactSphera Funds Management
Teambit analyzes code, meeting time, and interactions to measure and improve the performance of software development teams, delivering objective metrics.
AI & Machine LearningDeveloper ToolsSaaS
Paula Enei(Founder)in
Co-investorsGG Capital4BIO CapitalGeneral CatalystMRL Ventures FundNorwest Venture PartnersNovo Holdings
Practice Fusion provides a cloud-based electronic health record (EHR) platform for medical practices, with integrated medical billing, e-prescribing, and patient engagement tools.
Digital HealthHealthtechSaaSSan Francisco, US
Ryan Howard(Executive Officer, Director)in
BoardMark Goines(Director)Beth Seidenberg(Director)inMichael Harden(Director)Cora Tellez(Director)
Co-investorsBand of AngelsCanvas VenturesLongitude CapitalWestern Technology InvestmentArtis VenturesFelicis Ventures+6 more
Recovery Centers of America provides inpatient and outpatient addiction treatment, including detox, residential care, PHP/IOP outpatient programs, telehealth, and sober living, along with dual diagnosis and mental health care.
Digital HealthHealthtechMental Health
BiotechLexington, US
Victoria M. Richon(Executive Officer, Director)in
BoardCameron Wheeler(Director)Jonathan Root(Director)Laurence Lasky(Director)
Co-investorsAvego BioScience CapitalOUP (Osage University Partners)Peregrine VenturesAbbVieJJDCNovartis Venture Fund+3 more
SentreHeart appears to now redirect to AtriCure, Inc., a medical device company.
BiotechHardwareHealthtechMedical DevicesRedwood City, US
Russell Seiber(Executive Officer, Director)inPam Simons(Executive Officer)inGreg Fung(Executive Officer)Robert Strasser(Executive Officer)in
BoardPhil Young(Director)inVictor Tong(Director)
Co-investorsDecheng CapitalProspect Venture PartnersUS Venture PartnersU.S. Venture PartnersVivo Capital
Brooklyn, US
Marah Lidey(Executive Officer, Director)Naomi Hirabayashi(Executive Officer, Director)
BoardVictoria Song(Director)
Co-investorsComcast VenturesLaunchCapitalFidelity InvestmentsOaktreeSumitomo Corporation
ShineMed pursues a step-by-step commercialization approach to fusion energy, aiming to prove market value at each stage while generating revenue toward the goal of clean, abundant fusion power.
CleantechDeep TechEnergyHealthtechJanesville, US
Gregory Richard Piefer(Executive Officer, Director)Katrina Pitas(Executive Officer)Darin Janecek(Executive Officer)Anton Asmuth(Executive Officer, Director)James Costedio(Executive Officer)David A. Weissburg(Executive Officer, Director, Promoter)in
Co-investorsVenture ManagementWisconsin Investment PartnersBaillie GiffordKoch Disruptive Technologies
Somatus provides value-based, integrated kidney care and a congestive heart failure management solution for patients, providers, and health plan partners.
Digital HealthHealthtechMclean, US
Ikenna Okezie(Executive Officer, Director)inAlexander Houlday(Executive Officer)inStacey Queen-Pyndell(Executive Officer)Larry Renfro(Interim President & CEO)
BoardAnna Haghgooie(Director)Anthony Welters(Director)
Co-investorsFlare Capital PartnersOptum VenturesHealthQuest CapitalBlue Venture FundsDefy PartnersLongitude Capital+7 more
Soon is a portfolio management platform that automates buying and selling of assets across multiple exchanges using strategies like dollar-cost averaging and tax-loss harvesting.
Crypto & Web3FintechSalt Lake City, US
Michael Shattuck(Founder)inAaron BylundChris Lovato
Co-investorsIdeashipSoma CapitalY CombinatorDragon CapitalFalls FintechFidelity Investments+2 more
Strata Oncology develops precision oncology biomarkers and predictive diagnostic tools for cancer treatment, including treatment response scores for antibody-drug conjugates (ADCs) and an Immunotherapy Response Score for anti-PD-1/PD-L1 therapies.
AI & Machine LearningBiotechDigital HealthMedical DevicesAnn Arbor, US
Daniel Rhodes(Executive Officer, Director)Dan Rhodes(Founder)inScott Tomlins(Founder)inMatthew Martin(Executive Officer)Jeffrey Williams(Executive Officer, Director)
BoardChristopher O'Donnell(Director)in
Co-investorsArboretum VenturesBaird CapitalMerck Global Health Innovation FundMSD Global Health Innovation FundPfizer Venture InvestmentsWellington Management+1 more
Synthekine is a clinical-stage biotechnology company using protein engineering platforms to develop cytokine-based immunotherapies designed to preserve therapeutic efficacy while avoiding toxicities linked to cytokine pleiotropy.
BiotechHealthtech
K. Christopher Garcia(Founder)Susan Molineaux(CEO)inMartin Oft(Chief Scientific Officer)inNaiyer Rizvi(Chief Medical Officer)inGregory(Chief Technical Officer)Geoff(Chief Business Officer)
Co-investorsSamsara BioCapitalThe Column GroupBain Capital Life SciencesCanaan PartnersRA CapitalTCG Crossover+2 more
Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.
BiotechCambridge, US
Nancy Simonian(CEO)Peter Wirth(Director)Mark Alles(Director)Philip Sharp(Director)Richard A. Young(Director)Sue Gail Eckhardt(Director)
Co-investorsAisling CapitalARCH Venture PartnersQuan CapitalAlexandriaAlly Bridge GroupBain Capital+11 more
Endologix develops medical devices and therapies for treating vascular disease, focusing on interventions such as EVAR (endovascular aneurysm repair) procedures.
HardwareHealthtechMedical DevicesSanta Rosa, US
Michael V. Chobotov(Executive Officer)inSHARI L. O'QUINN(Executive Officer)inMichael R. Kramer(Executive Officer)KIMBERLEY ELTING(Executive Officer)CHRISTOPHER CHAVEZ(Executive Officer, Director)VIVEK K. JAYARAMAN(Executive Officer)in
Co-investors415 CapitalKaiser Permanente VenturesNew Enterprise Associates (NEA)SR One Capital Management
Vanta provides a security and compliance platform that helps companies improve their security posture and demonstrate compliance to auditors.
AI & Machine LearningCybersecurityEnterprise SoftwareSaaSSan Francisco, US
Christina Cacioppo(CEO & Founder)inBrittany Rose(Executive Officer)Erik Goldman(Founder)Rob Picard(Security Lead)inMatt Long(Senior Software Engineer)inAlex Marquez-Shaw(Recruiter)
Co-investorsAcrew CapitalAtlassian VenturesBeyond CapitalBonfire VenturesCraft VenturesFPV+25 more
Verana Health aggregates de-identified clinical data from a network of over 20,000 physicians in ophthalmology, urology, and neurology to power real-world evidence, clinical trial enablement, and quality reporting for pharmaceutical companies and healthcare providers using AI and machine learning.
AI & Machine LearningData & InfrastructureDigital HealthHealthtechSan Francisco, US
Mark Blumenkranz, MD(Co-Founder, Verana Health and Lagunita Biosciences)Sujay Jadhav(Chief Executive Officer)in
Co-investorsNovo HoldingsBreyer CapitalGV (Google Ventures)Merck Global Health Innovation FundMSD Global Health Innovation FundNat Turner+3 more
HealthtechMountain View, US
Kenneth Binmoeller, M.D.(Executive Officer, Director)inGreg Patterson(Executive Officer, Director)
BoardA. Barr Dolan(Director)Eric Sillman(Director)Anthony Natale, M.D.(Director)Avi Kometz(Director)
Co-investorsAPERTURE Venture PartnersATEL VenturesThird Point VenturesAscent Biomedical VenturesThird PointWestern Technology Investment
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Aprecia PharmaceuticalsConventus OrthopaedicsHumanity Health, Inc.Iowa ApproachPerfect HealthSpringtide Child DevelopmentAltus PharmaceuticalsAtlas Data StorageAtlasBaseAveXisBitterroot BioBlade TherapeuticsBluefin BiomedicineChondrial TherapeuticsCOTA HealthcareCovagen AGEpion HealthHana BiosciencesLiquid WireMMINeomorphNeuroFlowPairwise PlantsPerceive BiotherapeuticsPerceive PharmaPhoenix Nuclear LabsPipeline HealthPQ BypassRadianceRay TherapeuticsReady RespondersRelation TherapeuticsSequel TherapeuticsSpark TherapeuticsV-WaveVanova HealthVibliome TherapeuticsVicinitas TherapeuticsVital AccessZed Industries剂泰科技 (METiS TechBio)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 18
16 IPOs · 2 acquisitions · showing 15BiomxNYSE: PHGEBlack Diamond Therapeutics, IncNASDAQ: BDTXCabaletta BioNASDAQ: CABAEdgewise TherapeuticsNASDAQ: EWTXEditas MedicineNASDAQ: EDITFoghorn TherapeuticsNASDAQ: FHTXGenedxNASDAQ: WGSKiniksaNASDAQ: KNSAMirum PharmaceuticalsNASDAQ: MIRMPacific Biosciences of CaliforniaNASDAQ: PACBParabilis MedicinesNASDAQ: PBLSScynexisNASDAQ: SCYXXilio TherapeuticsNASDAQ: XLOCovagen AGacq. by Johnson & JohnsonTrivascularacq. by Endologix
Portfolio news
latest coverage across their companies
ElevenLabs · techcrunch.com · Sep 30, 2026
Black Diamond Therapeutics, Inc · finance.yahoo.com · Sep 2, 2026
Platanus · altss.com · Aug 11, 2026
Vanta · fortune.com · Apr 29, 2026
Foghorn Therapeutics · globenewswire.com · Jan 10, 2026
Lark · ycombinator.com · Dec 4, 2025
Fund performance · per public LP disclosures
as of Jun 2024| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Deerfield Private Design Fund IVLPs: Florida State Board of Administration, Robert Wood Johnson Foundation | 2007 | — | 7.9% | 1.45x | 0.11x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
IPO stake values · per SEC filings · 7
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Edgewise Therapeutics | 7.0% | $16.00 | Mar 2021 | $52.9M |
| Pacific Biosciences of California | 3.9% | $16.00 | Oct 2010 | $32.4M |
| Editas Medicine | 4.8% | $16.00 | Feb 2016 | $27.4M |
| Xilio Therapeutics | 5.7% | $16.00 | Oct 2021 | $24.2M |
| Kiniksa | 6.7% | $18.26 | Feb 2019 | $22.4M |
| Cabaletta Bio | 3.9% | $11.00 | Oct 2019 | $10.2M |
| Scynexis | 3.8% | $7.70 | Apr 2015 | $3.9M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Public market activity · per SEC filings
what is this? ⓘ59 insider ownership filings (Forms 3/4/5)
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- How many investments has Deerfield Management Company made?
- Deerfield Management Company has 125 tracked investments, 18 of which have exited, including 12 dated in the last 24 months.
- What stage does Deerfield Management Company invest at?
- Deerfield Management Company invests at the Seed, Series A, Series B, Growth, Late Stage stages.
- What sectors does Deerfield Management Company focus on?
- Deerfield Management Company focuses on AI & Machine Learning, Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Deerfield Management Company located?
- Deerfield Management Company is headquartered in New York, US.
- Does Deerfield Management Company lead rounds?
- Deerfield Management Company has led 14 of the 25 rounds where its role is on record.
- Who does Deerfield Management Company co-invest with?
- Deerfield Management Company most often shares deals with GV (Google Ventures), 8VC, Breyer Capital, among 37 tracked co-investors.
Images
Co-investors · 38
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
Optum Ventures is a healthcare-focused venture capital firm affiliated with UnitedHealth Group's Optum platform, investing in emerging healthcare and digital health companies across the US and globally.
OUP (Osage University Partners) is a venture firm that invests in science-driven startups commercializing deep technology innovations emerging from university research and breakthrough science.
US Venture Partners (USVP) is an early-stage venture capital firm investing in information technology and healthcare companies, with four decades of investing experience.
5AM Ventures is a life science venture capital firm founded in 2002 that funds and builds next-generation life sciences companies, focusing on biopharmaceuticals, drug delivery technologies, and life science instruments.
MPM BioImpact combines 30+ years of biotech venture capital expertise with impact investing and public market experience, managing early-stage venture funds, private/public impact funds, and a public equities fund focused on transforming patient outcomes.
Vivo Capital is a global healthcare-focused investment firm operating a multi-strategy platform spanning venture capital, private equity, and public equity. It aims to expand healthcare access and drive innovation through its 'Ecosystem Strategy.'
▶26 more co-investors
Andera PartnersFranklin TempletonSteelSky VenturesSequoia CapitalDCVC (Data Collective)Canaan PartnersObvious VenturesFlare Capital PartnersCity LightNovartis Venture FundRoche Venture FundRiverVest Venture PartnersMerck Global Health Innovation FundAPERTURE Venture PartnersTiger Global ManagementOak HC/FTVast VenturesS32Northpond VenturesFrazier Healthcare PartnersKing River CapitalBain Capital VenturesC2 InvestmentsParadigmHaun VenturesDomain Associates
Firms observed investing alongside Deerfield Management Company, from public investor directories. Shared companies are the overlap with Deerfield Management Company's recorded portfolio.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Menlo Ventures is an early-stage venture capital firm backing transformative technology companies, with a strong current emphasis on artificial intelligence across enterprise, healthcare, and consumer markets.
Ambix is a healthcare-focused investment firm that provides funding, strategy, and hands-on support to companies developing medical tools, devices, biochemistry-based technologies, and digital health applications. It also builds companies of its own.
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.